La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Rezolute a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Rezolute..

Rezolute (NASDAQ:RZLT) Azioni, Catena delle Opzioni

REZOLUTE INC

Rezolute

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Rezolute Inc

<a href="https://www.youtube.com/watch?v=0-ScnX6xWg0">https://www.youtube.com/watch?v=0-ScnX6xWg0</a>

Macro Economic Events

News

Politics

Economics

General

Gabon President Says We Would Like Raw Mineral Resources To Be Tapped; Our Market Is Open

<a href="https://www.bloomberg.com/news/articles/2025-07-09/apple-readies-first-upgrade-to-its-struggling-vision-pro-headset?srnd=undefined">https://www.bloomberg.com/news/articles/2025-07-09/apple-readies-first-upgrade-to-its-struggling-vision-pro-headset?srnd=undefined</a>

AAPL

'Apple Readies First Upgrade to Its Struggling Vision Pro Headset'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-07-09/openai-closes-6-5-billion-deal-to-buy-jony-ive-s-device-startup?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-09/openai-closes-6-5-billion-deal-to-buy-jony-ive-s-device-startup?srnd=homepage-americas</a>

MSFT

'OpenAI Closes $6.5 Billion Deal to Buy Jony Ive's Device Startup'- Bloomberg

Macro Notification

Liberia President Says Wants To See American Investment In His Country

Econ #s

USA 10-Year Note Auction for Jun 4.362% vs 4.421% Prior

UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is under renewed legal pressure as shareholders file additional lawsuits, many of which reference a federal investigation into the company's Medicare billing practices reported by the Wall Street <a href="https://www.benzinga.com/news/health-care/25/07/46232120/congress-is-buying-into-unitedhealth-46-crash-what-do-they-know-that-wall-street-doesnt">Journal in May.</a>
<h2 class="wp-block-heading">Details of the Latest Lawsuit</h2>
Steve Silverman, a UnitedHealth shareholder since 2003, filed a derivative lawsuit last week in federal court in Minnesota. In a derivative suit, a shareholder brings claims on behalf of the company against its own leadership, alleging harm to the corporation itself.
Read Next: <a href="https://www.benzinga.com/news/politics/25/07/46308025/get-ready-for-800-hours-of-blackouts-trumps-doe-warns?utm_source=articleShare">Get Ready For 800 Hours Of Blackouts, Trump&#8217;s DOE Warns</a>&nbsp;
Silverman's complaint accuses UnitedHealth's leadership, including CEO Stephen Hemsley, former CEO Andrew Witty and several board members, of:
<ul class="wp-block-list">
<li>Breaching their fiduciary duties</li>
<li>Engaging in insider trading</li>
<li>Unjust enrichment</li>
<li>Violating the Securities Exchange Act of 1934</li>
</ul>
The lawsuit references multiple media reports about UnitedHealth's billing practices, which culminated in the Wall Street Journal article that revealed the Department of Justice was preparing a criminal probe into the insurer's Medicare operations. 
"Despite repeated warnings, UnitedHealth's reliance on inflated coding practices continued through at least 2023 and apparently into 2024," Silverman's lawsuit claimed, according to Insurance Newsnet.&nbsp;
"These tactics yielded billions of dollars in excessive reimbursements, a sum so large that it vastly inflated the Company's financial results and stock price," the lawsuit alleges.
UnitedHealth has not commented on the lawsuit. In response to the Wall Street Journal's reporting, the company stated it had not been notified of any DOJ investigation and defended the integrity of its Medicare Advantage program.
Read Next: <a href="https://www.benzinga.com/markets/tech/25/07/46322945/the-curious-case-of-circle-stock-wall-street-cant-agree-on-the-future-of-finance?utm_source=articleShare">The Curious Case Of Circle Stock: Wall Street Can&#8217;t Agree On The Future Of Finance</a>
<h2 class="wp-block-heading">Additional Shareholder Actions</h2>
Other investors have filed similar lawsuits:
<ul class="wp-block-list">
<li>Joseph Crognale filed a complaint on June 30, naming the same 14 defendants as Silverman.</li>
<li>Merry Kogut filed a derivative suit on June 14, alleging that UnitedHealth's leadership failed to disclose a Department of Labor investigation in late 2023. Kogut claims the company repurchased $7.3 billion in stock at inflated prices during this period, and that executives profited from share sales while the DOJ probe was still secret.</li>
</ul>
Kogut's lawsuit alleges that Hemsley made $211.5 million and Witty $11 million from stock sales before the DOJ investigation became public knowledge.
All three <a href="https://www.benzinga.com/general/health-care/25/05/45305392/unitedhealth-investors-claim-company-hid-profit-impact-of-ceos-murder">lawsuits center</a> on UnitedHealth's Medicare billing and reporting practices. Plaintiffs argue that while the company's Medicare business has been highly profitable, it has also attracted negative attention that has hurt its stock price.
<h2 class="wp-block-heading">UNH in Turmoil</h2>
UnitedHealth is currently facing a series of challenges, including these lawsuits, a DOJ investigation, <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push">regulatory change</a>s from the Trump administration and recent leadership upheaval.&nbsp;
UnitedHealth CEO Andrew Witty resigned in May, and the company withdrew its previous earnings forecast less than a month after issuing it.&nbsp;
Additionally, the Wall Street Journal released<a href="https://www.benzinga.com/news/legal/25/07/46316016/unitedhealth-whistleblowers-allege-medicare-misconduct"> a new report</a> on Wednesday, which claims that former UnitedHealth employees told DOJ investigators that the company encouraged the capture of certain lucrative diagnoses during patient assessments.
UnitedHealth Group is set to report its second-quarter earnings and updated guidance on July 29. 
UNH shares have fallen more than 40% year-to-date, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, and were trading at $302.10 at the time of publication on Wednesday.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46284237/sofi-ready-to-capture-the-opportunity-as-trumps-big-beautiful-plan-restricts-federal-student-loans?utm_source=articleShare">SoFi Ready To &#8216;Capture The Opportunity&#8217; As Trump&#8217;s &#8216;Big, Beautiful&#8217; Plan Restricts Federal Student Loans</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Legal

Management

Movers

Trading Ideas

UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge

<h3>Gainers</h3>
<ul>
<li>Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) shares moved upwards by 28.8% to $7.7 during Wednesday's regular session. The company's market cap stands at $80.8 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares rose 26.43% to $21.11. The market value of their outstanding shares is at $224.4 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock increased by 19.65% to $1.4. The company's market cap stands at $47.0 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares moved upwards by 18.51% to $22.18. The company's market cap stands at $364.4 million. </li>
<li>Golden Sun Health Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) shares increased by 17.47% to $3.03. The market value of their outstanding shares is at $5.1 million. </li>
<li>Kandal M Venture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMFC#NASDAQ">FMFC</a>) shares increased by 15.63% to $5.98. The market value of their outstanding shares is at $93.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares declined by 24.8% to $0.19 during Wednesday's regular session. The company's market cap stands at $12.9 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock fell 22.49% to $0.16. </li>
<li>Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) shares declined by 13.46% to $75.11. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Viomi Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) stock fell 12.1% to $2.4. The company's market cap stands at $186.2 million. </li>
<li>ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) stock fell 11.95% to $3.58. The market value of their outstanding shares is at $900.1 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock declined by 10.8% to $2.52. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPSM

FMFC

GROV

GSUN

KRUS

MULN

NEGG

RERE

VIOT

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock increased by 225.2% to $1.09 during Wednesday's regular session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock increased by 169.54% to $7.17. The market value of their outstanding shares is at $3.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares increased by 72.81% to $3.15. The market value of their outstanding shares is at $34.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 43.07% to $0.08. The company's market cap stands at $21.2 million. </li>
<li>Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) stock moved upwards by 32.72% to $86.46. The company's market cap stands at $4.1 billion. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares moved upwards by 29.08% to $8.81. The company's market cap stands at $38.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares fell 37.7% to $7.97 during Wednesday's regular session. The company's market cap stands at $519.7 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares declined by 27.43% to $6.09. The company's market cap stands at $229.0 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock decreased by 17.44% to $0.64. The market value of their outstanding shares is at $3.6 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares declined by 17.12% to $114.24. The market value of their outstanding shares is at $767.1 million. </li>
<li>Pelthos Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#AMEX">PTHS</a>) stock declined by 14.09% to $17.08. The company's market cap stands at $13.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 12.34% to $0.69. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

BSGM

CLDI

EVOK

KZIA

NCNA

NUTX

PTHS

RXST

RYTM

WINT

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) stock rose 27.4% to $1.81 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) stock rose 26.06% to $0.61. The market value of their outstanding shares is at $4.7 million. </li>
<li>Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) shares rose 19.21% to $28.97. The company's market cap stands at $5.5 billion. </li>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) shares rose 18.74% to $2.85. The company's market cap stands at $36.4 million. </li>
<li>FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) stock increased by 16.58% to $11.46. The company's market cap stands at $187.9 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock rose 15.46% to $0.04. The company's market cap stands at $1.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) stock fell 29.2% to $4.92 during Wednesday's regular session. The market value of their outstanding shares is at $587.6 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock decreased by 21.9% to $1.32. The company's market cap stands at $42.5 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares declined by 20.7% to $0.36. The company's market cap stands at $15.7 million. </li>
<li>Arrive AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) stock declined by 13.42% to $9.1. The company's market cap stands at $346.7 million. </li>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares declined by 13.15% to $3.21. The market value of their outstanding shares is at $128.7 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) stock fell 10.98% to $20.19. The market value of their outstanding shares is at $506.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

ARAI

CIGL

EVTL

MCRP

PLUG

RAIL

RYDE

SPAI

WLGS

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock increased by 41.8% to $4.78 during Wednesday's regular session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares rose 27.76% to $0.34. The market value of their outstanding shares is at $17.3 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock rose 17.96% to $0.72. The company's market cap stands at $6.1 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares increased by 15.91% to $3.6. The market value of their outstanding shares is at $22.8 million. </li>
<li>Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) shares increased by 15.87% to $5.4. The market value of their outstanding shares is at $38.2 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock rose 13.76% to $2.48. The market value of their outstanding shares is at $72.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock declined by 45.6% to $60.63 during Wednesday's regular session. The market value of their outstanding shares is at $5.7 billion. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock decreased by 23.86% to $4.5. The market value of their outstanding shares is at $124.6 million. </li>
<li>UTStarcom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTSI#NASDAQ">UTSI</a>) stock fell 15.33% to $2.21. The market value of their outstanding shares is at $24.6 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares decreased by 14.65% to $1.59. The company's market cap stands at $23.3 million. </li>
<li>Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares fell 14.38% to $12.99. The market value of their outstanding shares is at $451.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) shares decreased by 11.42% to $4.27. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

AUUD

BMNR

BTCS

MINM

MLGO

PCLA

SAGT

SOBR

TDTH

UTSI

12 Information Technology Stocks Moving In Wednesday's Intraday Session

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Jackson Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JXN#NYSE">JXN</a>) with a Market Perform and raises the price target from $100 to $102.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on Jackson Finl, Raises Price Target to $102

Workhorse Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>), a technology company specializing in electric vehicles and drone technology for last-mile delivery, is currently experiencing significant volatility in its stock price. On Wednesday, the stock traded close to three times its 50-day moving average of $1.07.
This comes despite a year-to-date plunge of over 62% in its stock price. In contrast, the broader Russell 3000 Index, which includes Workhorse, has seen a 6% gain year-to-date.
Several factors have contributed to the fluctuations in Workhorse Group&#8217;s stock price throughout the year.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44559979/workhorse-stock-gains-as-fy24-loss-narrows-by-30" rel="noreferrer noopener">Workhorse Misses On FY24 Revenue And EPS, But Cost Cuts Narrow Losses</a>
<h2 class="wp-block-heading">Financial Performance and Market Position</h2>
Workhorse generates revenue through the manufacturing and sale of all-electric commercial delivery trucks, including Class 4 and 5/6 models like the W56.
However, the company has faced significant financial challenges, missing topline estimates in its previous two quarters and the bottom-line estimate in the last quarter.
For instance, in its first-quarter 2025 earnings reported on May 15, Workhorse <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45443786/workhorse-stock-slides-after-q1-miss-plans-to-cut-workforce-to-curb-cash-burn" rel="noreferrer noopener">announced sales</a> of $640,920, a considerable drop from $1.34 million a year prior and well below the analyst consensus estimate of $2.35 million.
Despite these revenue shortfalls, the company did manage to narrow its quarterly gross loss to $4.52 million, an improvement from $6.10 million a year ago.
Workhorse CEO Rick Dauch stated that, as of early 2025, the company secured purchase orders for 27 W56 step vans (available in 178- and 208-inch wheelbases) and six W4 CC/W750 trucks.
Looking ahead, Workhorse aims to sell more trucks in the second quarter of 2025 than in all of 2024, while simultaneously focusing on cash conservation and extending its financial runway, which includes plans to downsize its workforce to reduce monthly cash burn.
Workhorse competes in the electric vehicle market with rivals such as Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>).
<h2 class="wp-block-heading">Nasdaq Compliance and Reverse Stock Split</h2>
A significant event for Workhorse in the first half of 2025 was its struggle to maintain compliance with Nasdaq listing rules, which require a minimum $1 closing bid price.
To address this, the company implemented a 1-for-12.5 reverse stock split on March 17. This strategic move successfully boosted its share price, allowing Workhorse to regain compliance with <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44607973/whats-going-on-with-workhorse-group-stock-wednesday-3" rel="noreferrer noopener">Nasdaq listing rules</a> on April 2, after maintaining a minimum $1 closing bid price for 10 consecutive trading days.
<h2 class="wp-block-heading">Macroeconomic Environment and EV Incentives</h2>
The broader macroeconomic landscape and changes in electric vehicle incentives also play a role in Workhorse&#8217;s outlook. The recent approval by the U.S. House of Representatives of President Donald Trump&#8217;s &#8220;Big Beautiful Bill&#8221; eliminates the <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46279040/tax-credits-are-ending-can-mullens-global-push-and-crypto-pivot-win-over-ev-buyers" rel="noreferrer noopener">$7,500 tax credit</a> for new U.S.-made EVs.
With this tax break scheduled to expire on September 30, some automakers have already begun raising electric vehicle prices. This policy change could potentially prompt Workhorse to increase its own prices to protect its profit margins, thereby impacting customer demand.
Price Action: WKHS stock is trading higher by 15.5% to $3.13 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46314112/super-micro-accelerates-european-footprint-to-meet-exploding-ai-needs" target="_blank" rel="noreferrer noopener">Super Micro Accelerates European Footprint To Meet Exploding AI Needs</a></li>
</ul>
Image via Shutterstock

Tech

RIVN

WKHS

XPEV

Workhorse Rebounds After Nasdaq Scare, Stock Up 15%

Keefe, Bruyette &amp; Woods analyst Vasundhara Govil maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Market Perform and raises the price target from $81 to $85.

Keefe, Bruyette & Woods Maintains Market Perform on Global Payments, Raises Price Target to $85

WIIM

Sunrun shares are trading higher after Jefferies upgraded the stock from Underperform to Hold and raised its price target from $5 to $11.

Giving professional athletes the necessary tools to secure their financial futures through workshops on tech, entrepreneurship, and business was the primary goal of Fanatics' inaugural "Chapter: Next" career intensive.&nbsp;&nbsp;
Nearly two dozen athletes attended the event, which was hosted by sports merchandiser Fanatics and sports media and entertainment company Boardroom. The three-day business training camp <a href="https://www.fanaticsinc.com/press-releases/fanatics-amp-boardroom-team-up-to-launch-chapter-next-a-three-day-career-intensive-with-the-biggest-names-in-businessnbsp">promised to</a> "equip athletes and their associates with business skills needed for success beyond the court, field, and ice."&nbsp;
"This definitely opened my eyes," NBA Memphis Grizzlies guard Cole Anthony told <a href="https://www.cnbc.com/2025/06/23/fanatics-athlete-immersion-program-business-acumen-pro-athletes.html">CNBC</a>. "I'm already trying to do things on the business side with my partners, my family. It just motivates me more."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
A number of well-known business leaders acted as coaches for the camp, including Fanatics founder Michael Rubin, Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) CEO David Solomon, Raising Cane's founder Todd Graves, ESPN Chair Jimmy Pitaro, Boardroom CEO Rich Kleiman, and Apollo Global Management&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) co-founder Josh Harris.&nbsp;
These established founders and company leaders spoke to rooms full of athletes like Aaron Donald, who retired from the NFL after the 2023 season, having played for 10 years with the Los Angeles Rams. Donald is a part-owner of sports nutrition company Ready, but told CNBC he was excited about the opportunity to expand his business knowledge through the training camp.&nbsp;
"I think it's one of hell of an opportunity," Donald said. "I'm in a room with guys running companies worth billions of dollars. How many opportunities are you going to get to do that? You have to take advantage of all of those opportunities and knowledge."
Rich Kleiman, who founded Boardroom with NBA all-star Kevin Durant, told CNBC that's precisely the goal behind the "Chapter: Next" events.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
"I think it's great to be able to give them a bit of a blueprint," Kleiman said. "Being able to put them in the room with people that have the answers, that have done it, that lead industries. I think you get so much power and opportunity just from the information you get from watching, from learning and from being in these rooms and understanding how to move."
Fanatic's chief people officer, Toretha McGuire, agreed with Kleiman, telling CNBC that the goal of both "Chapter: Next" and the Athlete Immersion Program is to help professional athletes move from their "1.0 career" on the court to their "2.0 career" in the office.
"The opportunities they have in their 1.0 careers in terms of access and expanding their networks are going to be very critical," McGuire said.
Participants like Anthony say that the program has shown them the parallels between competing on the court and winning in a business sense.&nbsp;
"The common thing with everyone who has spoken to us and I've been able to talk to one-on-one is that every person I met here has been a grinder," Anthony told CNBC. "They make whatever it is they are passionate about, or what they are working on their priority. I think that's just dope to hear from other people I can relate to in that sense."
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

'One Hell Of An Opportunity,' Fanatic's Business Training Camp Helps Professional Athletes Become Business Tycoons

BitMine Immersion Technologies shares are trading lower after the company filed for a mixed shelf.

DASH

CNBC Halftime Report Final Trades: DoorDash, Westinghouse Air Brake Technologies, UnitedHealth Group

Financial giants have made a conspicuous bearish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) revealed 14 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $306,910, and 7 were calls, valued at $373,552.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $390.0 and $470.0 for Thermo Fisher Scientific, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Thermo Fisher Scientific options trades today is 146.1 with a total volume of 331.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Thermo Fisher Scientific's big money trades within a strike price range of $390.0 to $470.0 over the last 30 days.
<h3>Thermo Fisher Scientific Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752080492_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$26.3</td>
<td>$27.4</td>
<td>$450.00</td>
<td>$95.9K</td>
<td align="right">40</td>
<td align="right">55</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$26.5</td>
<td>$26.4</td>
<td>$26.5</td>
<td>$400.00</td>
<td>$76.8K</td>
<td align="right">368</td>
<td align="right">35</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$24.6</td>
<td>$23.8</td>
<td>$24.29</td>
<td>$420.00</td>
<td>$73.6K</td>
<td align="right">226</td>
<td align="right">31</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.4</td>
<td>$32.1</td>
<td>$32.0</td>
<td>$410.00</td>
<td>$64.0K</td>
<td align="right">223</td>
<td align="right">20</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$28.0</td>
<td>$26.4</td>
<td>$27.3</td>
<td>$450.00</td>
<td>$54.6K</td>
<td align="right">40</td>
<td align="right">75</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>Currently trading with a volume of 1,180,514, the TMO's price is down by -2.56%, now at $415.26. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $463.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Thermo Fisher Scientific, targeting a price of $480. 
&#x2A; An analyst from UBS downgraded its action to Neutral with a price target of $460. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Thermo Fisher Scientific, maintaining a target price of $450. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Thermo Fisher Scientific with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Behind the Scenes of Thermo Fisher Scientific's Latest Options Trends

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) became the first company ever to reach a $4 trillion market capitalization on Wednesday.
The impressive milestone, which puts Nvidia in the history books, was correctly predicted by Benzinga readers who picked between three tech giants in a recent poll.
What Happened: Nvidia traces its roots to <a href="https://www.benzinga.com/news/education/25/05/45701924/jensen-huang-founded-nvidia-at-a-dennys-now-hes-worth-600x-more-than-the-restaurant-chain" target="_blank" rel="noopener">being created at a</a> Denny's restaurant from which it has come a long way to become the most valuable company in the world &#8211; a title it has earned multiple times over the last two years.
Nvidia <a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club">became the ninth company </a>to pass the $1 trillion market capitalization milestone back in May 2023. The company then quickly surpassed more milestones over the last two years. It has fought back and forth with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to claim the title of the most valuable company on multiple occasions.
By hitting the $4 trillion milestone ahead of Microsoft and Apple, the company takes its place in history and disrupts a streak from Apple as the iPhone maker was the first U.S. company to be valued at $1 trillion, $2 trillion and $3 trillion market cap milestones.
In late June, <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46198021/nvidia-vs-microsoft-vs-apple-which-stock-reaches-4-trillion-first">Benzinga polled its readers</a> to ask which of these three tech giants would reach the $4 trillion market cap first.
The results on Instagram were:
<ul class="wp-block-list">
<li>Nvidia: 79%</li>
<li>Microsoft: 14%</li>
<li>Apple: 7%</li>
</ul>
The results on Threads were:
<ul class="wp-block-list">
<li>Nvidia: 79%</li>
<li>Microsoft: 17%</li>
<li>Apple: 4%</li>
</ul>
At the time, Nvidia had the market capitalization lead at $3.85 trillion, with Microsoft and Apple following closely behind at $3.70 trillion and $3.06 trillion, respectively.
Overall, Nvidia significantly won the polls with nearly 80% of the vote, ranking well ahead of the other two companies.
Here are the current market capitalizations as of Wednesday, July 9:
<ul class="wp-block-list">
<li>Nvidia: $4.00 trillion</li>
<li>Microsoft: $3.76 trillion</li>
<li>Apple: $3.14 trillion</li>
</ul>
Nvidia passing the milestone comes with the stock up 18.3% year-to-date and up 24.5% over the last year. Nvidia's gain of more than 1,400% over the last five years is significantly higher than that of its two peers.
Microsoft stock is up 20.4% year-to-date and 9.6% over the last 12 months. The stock has increased by 135% over the last five years.
Apple stock is down 13.7% year-to-date and 8.0% over the last 12 months. The stock has increased by 119% over the last five years.
Read Also: <a href="https://www.benzinga.com/general/social-media/24/03/37879478/humble-beginnings-like-nvidia-reddit-was-founded-inside-a-restaurant">Humble Beginnings: Like NVIDIA, Reddit Was Founded Inside A Restaurant</a>
What's Next: While Nvidia's rise to become the first $4 trillion company is historical, Benzinga readers are betting on more gains for the tech giant over the next 18 years.
President Donald Trump announced a plan to give parents $1,000 to invest for their children at birth. <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45973429/trump-wants-babies-to-get-1000-to-invest-at-birth-this-maginicent-7-stock-tops-poll-for-18-year-growth">Benzinga asked readers</a> which of the Magnificent 7 stocks they would invest $1,000 in today and hold for the next 18 years.
Here are the results:
<ul class="wp-block-list">
<li>Nvidia: 21%</li>
<li>Apple: 17%</li>
<li>Alphabet Inc: 14%</li>
<li>Meta Platforms: 14%</li>
<li>Amazon.com Inc: 12%</li>
<li>Microsoft: 12%</li>
<li>Tesla: 10%</li>
</ul>
The winner of the poll was Nvidia, with 21% of readers picking this stock as the one they would invest in and hold for the next 18 years to add wealth to their children&#8217;s investment account. Apple was a close second at 17%, with Alphabet and Meta tied for third at 14%.
Tesla ranked last in the poll of the Mag 7 stocks with 10% of the vote, while Microsoft and Amazon tied for fifth with 12%.
Benzinga readers are predicting big things for Nvidia in the future.
The company will report second-quarter financial results in late August. Nvidia<a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong"> previously guided for </a>second-quarter revenue to be $45.0 billion, +/- 2%, which includes a loss of $8.0 billion in H20 revenue due to the export controls.
Nvidia CEO Jensen Huang said at the time that the company's Blackwell AI supercomputer is in full-scale production and demand for the company's AI infrastructure is "incredibly strong."
&#8220;AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate. Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and NVIDIA stands at the center of this profound transformation," Huang said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/gaming/25/06/45776150/jensen-huang-says-nintendo-switch-2-has-ai-processors-to-enhance-gameplay-unlike-anything-weve-built-before">Jensen Huang Says Nintendo Switch 2 Has AI Processors To Enhance Gameplay: &#8216;Unlike Anything We&#8217;ve Built Before&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

NVDA

Nvidia Breaks $4 Trillion Barrier—Benzinga Poll Predicted It First

Deep-pocketed investors have adopted a bearish approach towards DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DASH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for DoorDash. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 21% leaning bullish and 42% bearish. Among these notable options, 2 are puts, totaling $79,962, and 12 are calls, amounting to $1,274,368.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $252.5 for DoorDash during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DoorDash's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DoorDash's whale trades within a strike price range from $110.0 to $252.5 in the last 30 days. 
<h3>DoorDash Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752080486_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$140.7</td>
<td>$138.4</td>
<td>$139.6</td>
<td>$120.00</td>
<td>$195.4K</td>
<td align="right">84</td>
<td align="right">44</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$140.8</td>
<td>$139.5</td>
<td>$139.5</td>
<td>$120.00</td>
<td>$195.3K</td>
<td align="right">84</td>
<td align="right">30</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$140.35</td>
<td>$139.45</td>
<td>$139.45</td>
<td>$120.00</td>
<td>$195.2K</td>
<td align="right">84</td>
<td align="right">58</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$142.0</td>
<td>$138.25</td>
<td>$139.42</td>
<td>$120.00</td>
<td>$195.1K</td>
<td align="right">84</td>
<td align="right">72</td>
</tr>
<tr>
<td>DASH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$141.15</td>
<td>$138.55</td>
<td>$139.65</td>
<td>$120.00</td>
<td>$97.7K</td>
<td align="right">84</td>
<td align="right">16</td>
</tr>
</tbody>
</table>

<h3>About DoorDash</h3>
Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.
Following our analysis of the options activities associated with DoorDash, we pivot to a closer look at the company's own performance.
<h3>Current Position of DoorDash</h3>
<ul>
<li>With a volume of 1,279,333, the price of DASH is up 1.81% at $245.83. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
<h3>Expert Opinions on DoorDash</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $262.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for DoorDash, targeting a price of $280. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on DoorDash with a target price of $260. 
&#x2A; Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for DoorDash, targeting a price of $265. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on DoorDash, which currently sits at a price target of $245. 
&#x2A; An analyst from Raymond James has elevated its stance to Strong Buy, setting a new price target at $260. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DoorDash, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

DoorDash Options Trading: A Deep Dive into Market Sentiment

Earnings

Press Releases

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ("HI")

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Comments

Rezolute

Rezolute (RZLT) Opzioni

Rezolute (NASDAQ:RZLT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO